Applications of Fmoc-Asp(OAll)-OH in Industrial Manufacturing

Fmoc-Asp(OAll)-OH serves as a specialized protected amino acid derivative widely used in high-precision chemical synthesis. Our production experience ensures consistency across diverse sectors such as peptide pharmaceuticals, active enzyme synthesis, diagnostic reagents, biomedical research, and peptide-functionalized materials. Below are detailed industrial applications, based on actual downstream practices and validation by end-users.

1. Peptide Active Pharmaceutical Ingredient (API) Synthesis

Pharmaceutical manufacturers utilize Fmoc-Asp(OAll)-OH during solid-phase peptide synthesis (SPPS) to introduce aspartic acid with orthogonally protected side chains. This enables precise sequence assembly, especially for APIs featuring aspartic acid residues that require posterior side-chain deprotection. Our material's high purity reduces sequence deletion risk and improves batch-to-batch integrity in GMP peptide drug manufacturing.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP General Chapter <1790> for Peptide APIs
• European Pharmacopoeia monograph 01/2015:1468
• FDA 21 CFR Part 211

Typical usage ratio

• 0.95–1.10 equivalents per aspartic acid position depending on SPPS loading and coupling efficiency

Downstream process integration

• Initial loading onto solid support during automated SPPS; after Fmoc group removal, coupling proceeds using HBTU/HATU or similar agents. OAll group remains until selective deprotection.

Final product types

• Peptide pharmaceutical APIs (e.g., semaglutide, liraglutide, buserelin)
• Generic peptide analogues for regulated markets
• Clinical-grade peptide intermediates

2. Enzyme Synthesis with Site-Specific Modifications

Biotechnology producers rely on Fmoc-Asp(OAll)-OH for constructing enzymes and protein mimetics with defined aspartic acid functionalities. The orthogonal protection allows for late-stage side-chain derivatization, critical in preparing enzymatic products where active site control is essential, such as protease inhibitors or modified lysozymes, for biochemical assays and industrial catalysis.

Industry compliance standards

• ISO 13485:2016 Medical Devices — Quality Management
• ISO 9001:2015 for Laboratory-Scale Production
• EudraLex Volume 4

Typical usage ratio

• 1.00 equivalent per designated aspartic acid site; may adjust (0.95–1.2) based on chain length and resin capacity.

Downstream process integration

• Insert at specific elongation steps in solid-phase or solution-phase protein synthesis; OAll group remains intact during N-terminal modifications, removed post-assembly for downstream conjugation.

Final product types

• Engineered enzymes with selective side-chain labeling
• Peptidyl biomarker standards for proteomic assays
• Customized biocatalysts for pharmaceutical transformation

3. Diagnostic Peptide Synthesis

Diagnostic reagent manufacturers use this material for creating peptides used in immunoassays, including epitope mapping, calibration standards, and quality controls. The OAll-protected side chain enables selective functionalization or linker introduction after main-chain assembly, supporting complex peptide diagnostics for ELISA, immunochromatography, and mass spectrometry panels.

Industry compliance standards

• ISO 13485:2016 for In Vitro Diagnostics
• CLSI EP05: Evaluation of Precision
• FDA 21 CFR Part 820 for Medical Devices

Typical usage ratio

• 0.98–1.05 equivalents for each aspartic acid residue, calculated relative to total resin active sites.

Downstream process integration

• Couple during SPPS for sequence definition; following chain elongation, selectively remove OAll group before attaching reporter groups or capture agents.

Final product types

• Peptide antigens for antibody screening
• Labeled peptide controls for in vitro diagnostics
• Synthetic epitope standards for clinical assay kits

4. Peptide-Functionalized Polymer Material Production

Producers of advanced polymer materials incorporate Fmoc-Asp(OAll)-OH to introduce controlled peptide moieties into polymers and hydrogels. The side chain OAll group provides a handle for spatially selective grafting post-polymerization, ensuring functionalized surfaces suitable for cell culture, biosensing, and drug delivery components.

Industry compliance standards

• ISO 10993-1: Biocompatibility evaluation of medical devices
• USP <87> Biological Reactivity Tests In Vitro
• ISO 9001:2015 for Industrial Polymer Processing

Typical usage ratio

• 0.2–3 wt% relative to total polymerizable units; ratio set by target surface density and functionalization requirements for biomedical end-use.

Downstream process integration

• Introduce protected amino acid directly into pre-polymerization mixtures or surface coupling; remove OAll after polymer formation to permit subsequent bio-conjugation.

Final product types

• Bioactive hydrogel scaffolds for tissue engineering
• Cell adhesion-promoting coatings
• Sensing membrane substrates for point-of-care devices